Skip to content
value.today

Omnicell, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, -2.9% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt or cash not on file: 0 to start with.

What today's price assumes

A market value of $1.7 B means free cash flow growing 2.6% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew -2.9% a year over the last three years.

Cash-flow value of the shares
$1.1 B
-33% against the market value
Value of the whole business
$1.1 B
before net debt
Value from after year 10
42%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-7.94%-5.44%-2.94%-0.44%2.06%
8.15%-39%-27%-12%+7%+30%
9.15%-47%-36%-24%-8%+10%
10.15%-52%-43%-33%-20%-4%
11.15%-56%-49%-40%-28%-15%
12.15%-60%-53%-45%-35%-24%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

Price to salesPrice to sales of Healthcare Information Services: $1.4 B to $8.0 B, median $2.2 BPrice to bookPrice to book of Healthcare Information Services: $1.5 B to $6.0 B, median $3.0 BCash-flow value$0 M$2.2 B$4.3 B$6.5 B$8.7 BMarket value $1.7 B

Your own DCF model

A full discounted-cash-flow model of Omnicell, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Healthcare Information Services

Multiples of its companies with a market value at most 60 days old, times Omnicell, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Omnicell, Inc.Applied toValue (25th to 75th)Companies
Price to sales1.2× / 1.9× / 6.8×1.4×revenue $1.2 B$1.4 B to $8.0 B14
Price to book1.2× / 2.4× / 4.9×1.4×book equity $1.2 B$1.5 B to $6.0 B14

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Omnicell, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

43.5×

Now below its median of 84.5×, in the bottom quarter of its range; range 27.8× to 917.9× over 24 months.

0×229×459×688×918×2020202120222023202420252026P/E 44×Median 84×

Price to sales

1.4×

Now below its median of 1.5×; range 1.1× to 8.0× over 28 months.

0×2×4×6×8×2020202120222023202420252026Price to sales 1×Median 2×

Price to book

1.4×

Now below its median of 1.5×; range 1.0× to 7.4× over 28 months.

0×2×4×6×7×2020202120222023202420252026Price to book 1×Median 1×

as of Oct 27, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 27, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$1.2 B$2 M$127 M$40 M$87 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$1.1 B$13 M$188 M$36 M$151 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$1.1 B$-20 M$181 M$41 M$140 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$1.3 B$6 M$78 M$48 M$30 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$1.1 B$78 M$232 M$29 M$203 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$892 M$32 M$186 M$23 M$163 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $1.7 B on Oct 27, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.